Core Points - Select Medical Holdings Corporation reported a revenue increase of 4.5% to $1,339.6 million for Q2 2025 compared to Q2 2024 [2] - Income from continuing operations, net of tax, rose 53.8% to $57.9 million for Q2 2025 [2] - The company declared a cash dividend of $0.0625 per share, payable on August 28, 2025 [13] Financial Performance - For the six months ended June 30, 2025, revenue increased 3.4% to $2,692.8 million compared to the same period in the prior year [3] - Adjusted EBITDA for the six months was $276.9 million, down from $290.5 million in the prior year [3] - Earnings per common share from continuing operations increased 52.0% to $0.76 for the six months ended June 30, 2025 [3] Segment Performance - Critical Illness Recovery Hospital Segment revenue decreased to $601.1 million for Q2 2025, down from $604.9 million in Q2 2024 [6] - Rehabilitation Hospital Segment revenue increased 17.2% to $313.8 million for Q2 2025 compared to Q2 2024 [8] - Outpatient Rehabilitation Segment revenue increased 3.8% to $327.6 million for Q2 2025 compared to Q2 2024 [11] Stock Repurchase and Dividend - The Board of Directors authorized a stock repurchase program of up to $1.0 billion [15] - During the first half of 2025, Select Medical repurchased 6,375,512 shares at a cost of approximately $96.5 million [16] Business Outlook - Select Medical expects revenue for fiscal year 2025 to be in the range of $5.3 billion to $5.5 billion [17] - Adjusted EBITDA is projected to be between $510.0 million and $530.0 million for 2025 [17]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Encompass Health Corporation due to allegations of violations of federal securities laws and unlawful business practices following negative reports about the company's hospital performance [1][3]. Group 1: Allegations and Impact - A New York Times article published on July 15, 2025, reported that Encompass's for-profit hospitals perform below average on key safety measures, with 34 facilities rated by Medicare as having significantly worse rates of potentially preventable readmissions [3]. - The article highlighted "alarming mistakes" that have led to patient fatalities, raising serious concerns about the company's operational practices [3]. - Following the publication of this article, Encompass's stock price dropped by $12.39, or 10.4%, closing at $107.28 per share, resulting in financial losses for investors [4]. Group 2: Legal Actions and Contact Information - Investors who purchased or acquired Encompass shares and suffered losses are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights and potential claims [1][5]. - The law firm specializes in representing individual and institutional investors in complex litigation, indicating a focus on protecting shareholder interests [6].

Financial Data and Key Metrics Changes - The company reported net income attributable to UHS per diluted share of $5.43 for Q2 2025, with adjusted net income per diluted share at $5.35 after adjustments [5][6] - Adjusted admissions to acute care hospitals increased by 2% year-over-year, while surgical volumes decreased slightly [5] - Same facility net revenues in the acute care hospital segment increased by 5.7% compared to Q2 2024, excluding the impact of the insurance subsidiary [5][6] - Cash generated from operating activities decreased by $167 million to $9 million in Q2 2025 compared to $1,076 million in Q2 2024 [8] - The company repurchased approximately 1.9 million shares at a total cost of about $332 million since 2019, representing 34% of outstanding shares [9] Business Line Data and Key Metrics Changes - Same facility net revenues at behavioral health hospitals increased by 5.4%, driven by a 4.2% increase in revenue per adjusted day [7] - Adjusted patient days in behavioral health were up 1.2% compared to the prior year's second quarter [8] - Operating expenses on a same facility basis increased by 3.1% year-over-year, excluding the impact of the insurance subsidiary [6] Market Data and Key Metrics Changes - The company noted a cannibalization impact on same facility volumes and revenues from the newly opened West Henderson Hospital [6] - The performance of the Las Vegas and District of Columbia markets showed some economic softness, impacting overall volumes [91] Company Strategy and Development Direction - The company is focusing on outpatient growth, aiming to capture a larger share of the outpatient behavioral care market [25][26] - New developments include a 96-bed behavioral hospital in Grand Rapids, Michigan, and a 41-bed substance use disorder treatment center in South Carolina, among others [12][13] - The company is also expanding its Signet Behavioral Health Network in the UK, adding six new facilities and 137 beds [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in adapting to potential Medicaid revenue reductions starting in 2028, emphasizing strategic shifts in the behavioral business [17][19] - The company anticipates that the impact of the One Beautiful Bill Act on Medicaid revenues will be manageable, with ongoing discussions with state representatives [20][21] - Management acknowledged challenges in the startup of Cedar Hill Regional Medical Center but remains optimistic about long-term prospects [11][30] Other Important Information - The company spent $5 million on capital expenditures in 2025, with 25% allocated to new replacement facilities in California and Florida set to open in 2026 [8] - The company has approximately $1 billion of available borrowing capacity under its revolving credit facility [9] Q&A Session Summary Question: Impact of Medicaid changes on EBITDA - Management indicated that reductions from Medicaid changes will not begin until 2028, allowing time to adjust business strategies, particularly in the behavioral segment [17][18] Question: Behavioral patient days split - Management noted that adjusted patient days have grown faster than unadjusted patient days, indicating outpatient growth is a significant opportunity [24][25] Question: Update on Cedar Hill's accreditation status - Management acknowledged startup losses of $25 million in Q2 for Cedar Hill, with another $25 million expected in the second half of the year, pending Medicare certification [30] Question: Behavioral pricing growth - Management confirmed that behavioral pricing growth has outperformed expectations, with a breakdown of 4.2% increase in pricing and 1.2% in adjusted patient days [50][52] Question: Long-term margin targets - Management expressed confidence in maintaining long-term margin targets despite upcoming challenges, emphasizing flexibility in programming adjustments [96][98] Question: Labor market challenges - Management reported that while wage inflation has decelerated, staffing challenges persist in certain markets, particularly in behavioral health [68][70]

Financial Data and Key Metrics Changes - The company reported net income attributable to UHS per diluted share of $5.43 for Q2 2025, with adjusted net income per diluted share at $5.35 after adjustments [4][6] - Adjusted admissions to acute care hospitals increased by 2% year-over-year, while surgical volumes decreased slightly [4] - Same facility net revenues in the acute care hospital segment increased by 5.7% compared to Q2 2024, excluding the impact of the insurance subsidiary [4] - Cash generated from operating activities decreased by $167 million to $909 million in Q2 2025 compared to $1,076 million in Q2 2024 [6] - The company spent $500 million on capital expenditures, with 25% allocated to new replacement facilities in California and Florida [6] Business Line Data and Key Metrics Changes - Same facility EBITDA increased by 10% in the acute care segment, driven by solid revenue and effective expense controls [5] - In the behavioral health segment, same facility net revenues increased by 5.4%, with a 4.2% increase in revenue per adjusted day [5] - Adjusted patient days in the behavioral health segment were up 1.2% compared to the prior year's second quarter [6] Market Data and Key Metrics Changes - The West Henderson Hospital, opened in late 2024, had a cannibalization impact on same facility volumes and revenues [5] - The company noted a slight decrease in surgical volumes, indicating potential market challenges [4] Company Strategy and Development Direction - The company is increasing its EPS guidance for 2025 by 7% to $20.50 per diluted share, driven by increased DPP reimbursement [10] - The company is focusing on outpatient growth in the behavioral segment, with plans to open 10-15 new outpatient facilities annually [42] - The company is developing new behavioral health hospitals in various locations, including Michigan and Pennsylvania, to expand its service offerings [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term prospects for the Cedar Hill Regional Medical Center despite initial startup challenges [11] - The company anticipates potential changes to Medicaid programs that could impact future revenues, with a projected reduction in net benefits starting in 2028 [8] - Management emphasized the ability to pivot and adapt to changes in the operating environment, drawing on past experiences during the pandemic [17][20] Other Important Information - The company repurchased approximately 1.9 million shares at a cost of $332 million since 2019, representing about 34% of outstanding shares [7] - The One Beautiful Bill Act includes significant changes to the Medicaid program, which may impact future revenues [8] Q&A Session Summary Question: Impact of Medicaid changes on EBITDA - Management confirmed the projected reduction of $360 million to $400 million in net benefits starting in 2028, with strategies to offset this through operational adjustments [15][17] Question: Behavioral health volume growth - Management noted that outpatient growth is a significant opportunity, with adjusted patient days growing faster than inpatient days [21][24] Question: Cedar Hill's startup losses - Management acknowledged $25 million in startup losses for Cedar Hill in Q2, with another $25 million expected in the second half of the year, but expressed optimism for future profitability [26][30] Question: Outpatient behavioral growth strategy - Management detailed plans to enhance outpatient services through step-down and step-in business models, aiming to capture a larger share of the outpatient market [38][42] Question: Labor market challenges - Management indicated that while wage inflation has slowed, staffing challenges persist, particularly in the behavioral segment [66][68] Question: DPP program updates - Management provided updates on ongoing discussions with CMS regarding the approval of DPP programs, emphasizing the potential for new programs despite legislative changes [70][72]

Core Viewpoint - The Hainan Provincial Health Commission is enhancing the service quality of the 12345 hotline to address public medical needs more effectively, ensuring that patient complaints and inquiries are handled promptly and efficiently [2][4]. Group 1: Service Improvement Measures - The establishment of a Medical Service Supervision Group at the Provincial People's Hospital aims to address patient inquiries and complaints directly, implementing a "first contact responsibility" system to ensure accountability [3][4]. - The hotline operates 24/7, and a new complaint management method was introduced, which includes clear processing norms and timelines, linking performance assessments to the handling of complaints [3][5]. - The number of complaints decreased from 966 to 649 between March and June, reflecting a monthly decline rate of 12.35%, with a 15.40% decrease in complaints through the 12345 platform [3][5]. Group 2: Systematic Changes and Future Plans - The Provincial Health Commission is pushing for a comprehensive optimization of medical service processes across the province, focusing on improving the quality of healthcare services and transforming the industry’s work ethic [4][5]. - The commission plans to enhance the capabilities of hotline staff and improve the quality management of the complaint handling process, integrating data analytics and AI to proactively address common issues [5].

Financial Performance - Reported net income attributable to Universal Health Services, Inc. (UHS) for Q2 2025 was $353.2 million, or $5.43 per diluted share, compared to $289.2 million, or $4.26 per diluted share in Q2 2024, reflecting a significant increase [1][2] - Net revenues for Q2 2025 increased by 9.6% to $4.284 billion from $3.908 billion in Q2 2024 [1] - Adjusted net income attributable to UHS for Q2 2025 was $347.9 million, or $5.35 per diluted share, compared to $292.6 million, or $4.31 per diluted share in Q2 2024 [2][36] Medicaid Reimbursements - Included in the reported and adjusted net income for Q2 2025 were approximately $101 million in net pre-tax incremental reimbursements related to Medicaid programs, with $58 million from the Tennessee Medicaid directed payment program and $43 million from other states' supplemental Medicaid programs [3] EBITDA Metrics - EBITDA net of noncontrolling interests (NCI) for Q2 2025 was $651.4 million, up from $573.2 million in Q2 2024 [6] - Adjusted EBITDA net of NCI for Q2 2025 was $642.9 million, compared to $578.7 million in Q2 2024 [6][37] Acute Care Services - In Q2 2025, adjusted admissions at acute care hospitals increased by 2.0%, and adjusted patient days increased by 1.1% compared to Q2 2024 [12] - Net revenues from acute care services on a same facility basis increased by 7.9% in Q2 2025 compared to Q2 2024 [12] Behavioral Health Care Services - For Q2 2025, adjusted admissions at behavioral health care facilities increased by 0.4%, while adjusted patient days increased by 1.2% compared to Q2 2024 [14][15] - Net revenues from behavioral health care services increased by 8.9% during Q2 2025 compared to Q2 2024 [15] Cash Flow and Liquidity - Net cash provided by operating activities for the first six months of 2025 was $909 million, down from $1.076 billion in the same period of 2024 [17] - As of June 30, 2025, UHS had $1.08 billion of available borrowing capacity under its revolving credit facility [18] Stock Repurchase Program - During Q2 2025, UHS repurchased 875,000 shares at an aggregate cost of approximately $150.8 million, with a total of 1.875 million shares repurchased for $331.5 million in the first six months of 2025 [20][21] Revised Operating Results Forecast - UHS revised its 2025 operating results forecast, estimating net revenues between $17.096 billion and $17.312 billion, and adjusted EBITDA net of NCI between $2.458 billion and $2.543 billion [22][25] - The revised forecast for adjusted EPS-diluted is estimated to be between $20.00 and $21.00 per share, reflecting increases over the original forecast [25]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices by Encompass Health Corporation and its officers or directors [1] Group 1: Allegations and Impact - A New York Times article published on July 15, 2025, alleged that Encompass's for-profit hospitals perform below average on key safety measures, including high rates of potentially preventable readmissions [3] - The article highlighted that Encompass owns 34 facilities rated by Medicare as having statistically significantly worse rates of potentially preventable readmissions [3] - Following the publication of the article, Encompass's stock price dropped by $12.39 per share, or 10.35%, closing at $107.28 per share on the same day [4]

Core Viewpoint - Encompass Health Corporation is under investigation for potential securities fraud and unlawful business practices following allegations of poor performance in safety measures at its facilities, leading to a significant drop in stock price [1][2][3]. Group 1: Investigation and Allegations - Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation regarding possible securities fraud or unlawful business practices [1]. - The New York Times reported that Encompass's for-profit hospitals perform below average on key safety measures, with 34 facilities rated by Medicare as having significantly worse rates of preventable readmissions [2]. Group 2: Stock Price Impact - Following the publication of the allegations, Encompass's stock price fell by $12.39 per share, representing a 10.35% decrease, closing at $107.28 per share on July 15, 2025 [3].

Core Insights - Community Health Systems, Inc. (CYH) reported a second-quarter 2025 adjusted loss of $0.05 per share, missing the Zacks Consensus Estimate of earnings of $0.05, but improved from a loss of $0.17 per share in the prior year [1][11] - Net operating revenues decreased by 0.2% year over year to $3.1 billion, surpassing the consensus mark by 3% [1][11] Operational Performance - The hospital count for Community Health was 70, down from 78 a year ago [3] - Patient days fell by 9.4% year over year, while the average length of stay decreased by 2.3% to 4.2 days [3] - The occupancy rate increased to 50.8% from 50% in the prior year [3] - Adjusted admissions declined by 8.3% year over year, with same-store adjusted admissions down by 0.7% [4][11] Financial Metrics - Total operating expenses decreased by 9.7% year over year to $2.6 billion, below the estimate of $2.7 billion [5] - Net interest expenses were $214 million, a decrease of 0.9% year over year, but higher than the estimate of $205.7 million [5] - Net income for the quarter was $320 million, significantly up from $26 million in the prior year [6] - Adjusted EBITDA declined by 1.8% year over year to $380 million, exceeding the estimate of $365.7 million [6] Divestitures and Assets - In 2025, the company divested ownership interests in several hospitals, including a 50% stake in two hospitals and full ownership of three others [7] - As of June 30, 2025, cash and cash equivalents stood at $456 million, up from $37 million at the end of 2024 [8] - Total assets decreased to $13.6 billion from $14.1 billion at the end of 2024, while long-term debt fell to $10.8 billion from $11.4 billion [8] Guidance for 2025 - The company anticipates net operating revenues between $12.3 billion and $12.6 billion for 2025, compared to $12.63 billion in 2024 [12] - Adjusted EBITDA is expected to be in the range of $1.45 billion to $1.55 billion, slightly lower than the 2024 level of $1.54 billion [12] - Net loss per share is projected to be between $0.40 and $0.10 in 2025 [12] - Estimated net cash from operating activities is between $600 million and $700 million, with capital expenditures anticipated in the range of $350 million to $400 million [13]

July 23, 2025 Earnings Presentation – 2nd Quarter, 2025 Disclaimer Statement By The Numbers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 that involve risk and uncertainties. All statements in this presentation other than statements of historical fact, including statements regarding projections, expected ...